Zenzedi (Dextroamphetamine Sulfate) Patent Expiration, LOE Window & CMS Spending

Zenzedi (Dextroamphetamine Sulfate) by Arbor/Azurity: Off-Patent Genericized (AB Competition), 2 AB generics, $835K 2024 CMS Part D & Medicaid spend, and 14 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorArbor/Azurity
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$835K
2024 Medicare Part D Spend$281K
2024 Medicaid Spend$555K
Reported Wholesale Price Change (CA SB 17)14 WAC filings (max 49.9% 2-yr change)